美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

GraniteShares YieldBOOST Biotech ETF

20.42

+0.08380.41%

盤後：20.420.00000.00%16:10 EDT

成交量：1,645

成交額：3.36萬

市值：102.08萬

市盈率：- -

高：20.52

開：20.27

低：20.27

收：20.33

52周最高：25.28

52周最低：20.27

股本：5.00萬

流通股本：5.00萬

量比：0.61

換手率：3.29%

股息：4.92

股息率：24.11%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

藥聞 | 英硅智能上市後首份半年報扭虧創新藥研發加速擁抱AI

聯環藥業上半年扭虧為盈集採續採與創新藥研發協同推進

南京諾令生物科技股份有限公司向港交所提交上市申請書，獨家保薦人為建銀國際。

據港交所文件，維眸生物科技股份有限公司-B向港交所提交上市申請書。

博濟醫藥2026年半年報：創新藥研發需求復甦，在手訂單充足，經營現金流明顯下滑

美股開盤｜三大指數升跌不一；Meta升逾3%、小鵬汽車升逾3%；生物科技股活躍

港股早評：三大指數高開逾1.1%，生物科技股、黃金股大漲

AI生物科技股Twist Bioscience升逾22%

受利好消息提振，美股生物科技股普漲

深圳易慕峯生物科技股份有限公司向港交所提交IPO申請，華泰金融控股（香港）為保薦人兼整體協調人。

中國銀河證券：實驗動物為創新藥研發剛需小鼠+猴雙主線高景氣

百花醫藥股價嚴重異常波動：主營小分子化學仿製藥CRO業務不涉及創新藥研發

百花醫藥(600721.SH)：不涉及創新藥研發

百花醫藥(600721.SH)：不涉及創新藥研發

東方證券：AI重構創新藥研發底座國內相關產業鏈公司亦有望受益

創新藥研發加速遇「猴荒」

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/BIOY/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BIOY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BIOY\",,,,,undefined,":{"symbol":"BIOY","market":"US","secType":"STK","nameCN":"GraniteShares YieldBOOST Biotech ETF","latestPrice":20.415,"timestamp":1789416000000,"preClose":20.3312,"halted":0,"volume":1645,"hourTrading":{"tag":"盘后","latestPrice":20.415,"preClose":20.415,"latestTime":"16:10 EDT","volume":8,"amount":163.180008,"timestamp":1789416603520,"change":0,"changeRate":0,"amplitude":0.001714},"delay":0,"changeRate":0.004121743920673649,"floatShares":50001,"shares":50001,"eps":0,"marketStatus":"盤後交易","change":0.0838,"latestTime":"09-14 16:21:38 EDT","open":20.27,"high":20.52,"low":20.27,"amount":33641,"amplitude":0.012296,"askPrice":25.7,"askSize":200,"bidPrice":15.42,"bidSize":200,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1789430400000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":20.3312,"nav":20.361652,"aum":1018102.950152,"dividendRate":0.241102,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":20.415,"preClose":20.415,"latestTime":"16:10 EDT","volume":8,"amount":163.180008,"timestamp":1789416603520,"change":0,"changeRate":0,"amplitude":0.001714},"volumeRatio":0.610118},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BIOY\",,,,,undefined,":{"symbol":"BIOY","floatShares":50001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.610118,"shares":50001,"dividePrice":4.9221,"high":20.52,"amplitude":0.012296,"preClose":20.3312,"low":20.27,"week52Low":20.27,"pbRate":"--","week52High":25.28,"institutionHeld":0,"latestPrice":20.415,"eps":0,"divideRate":0.241102,"volume":1645,"delay":0,"ttmEps":0,"open":20.27,"prevYearClose":25.12,"prevWeekClose":20.3312,"prevMonthClose":21.2744,"prevQuarterClose":23.15,"fiveDayClose":21.1669,"twentyDayClose":21.065,"sixtyDayClose":23.155},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BIOY\",params:#limit:5,,,undefined,":[{"date":"2026-09-11","symbol":"BIOY","amount":0.24645,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-11","defaultRemindTime":1789133400000,"name":"GraniteShares YieldBOOST Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-15","payableDate":"2026-09-11","currency":"USD","dateTimestamp":1789099200000,"payDate":"2026-09-15"},{"date":"2026-09-04","symbol":"BIOY","amount":0.24791,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-04","defaultRemindTime":1788528600000,"name":"GraniteShares YieldBOOST Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-09","payableDate":"2026-09-04","currency":"USD","dateTimestamp":1788494400000,"payDate":"2026-09-09"},{"date":"2026-08-28","symbol":"BIOY","amount":0.24728,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-28","defaultRemindTime":1787923800000,"name":"GraniteShares YieldBOOST Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-01","payableDate":"2026-08-28","currency":"USD","dateTimestamp":1787889600000,"payDate":"2026-09-01"},{"date":"2026-08-21","symbol":"BIOY","amount":0.24904,"announcedDate":"2026-08-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-21","defaultRemindTime":1787319000000,"name":"GraniteShares YieldBOOST Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-25","payableDate":"2026-08-21","currency":"USD","dateTimestamp":1787284800000,"payDate":"2026-08-25"},{"date":"2026-08-14","symbol":"BIOY","amount":0.24507,"announcedDate":"2026-08-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-14","defaultRemindTime":1786714200000,"name":"GraniteShares YieldBOOST Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-18","payableDate":"2026-08-14","currency":"USD","dateTimestamp":1786680000000,"payDate":"2026-08-18"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BIOY\",market:\"US\",,,undefined,":[{"executeDate":"2026-05-08","recordDate":"2026-05-08","paymentDate":"2026-05-12","value":0.28187,"currency":"USD"},{"executeDate":"2026-05-15","recordDate":"2026-05-15","paymentDate":"2026-05-19","value":0.29042,"currency":"USD"},{"executeDate":"2026-05-22","recordDate":"2026-05-22","paymentDate":"2026-05-27","value":0.2758,"currency":"USD"},{"executeDate":"2026-05-29","recordDate":"2026-05-29","paymentDate":"2026-06-02","value":0.27453,"currency":"USD"},{"executeDate":"2026-06-05","recordDate":"2026-06-05","paymentDate":"2026-06-09","value":0.2676,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BIOY\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BIOY\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2663282078","title":"藥聞 | 英硅智能上市後首份半年報扭虧 創新藥研發加速擁抱AI","url":"https://stock-news.laohu8.com/highlight/detail?id=2663282078","media":"新华财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663282078?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 15:35","pubTimestamp":1788161758,"startTime":"0","endTime":"0","summary":"新华财经上海8月31日电（记者杜康）作为AI制药领域代表性企业之一，英硅智能（03696.HK）日前发布2026年度中期业绩报告。上半年，公司实现总营收1.063亿美元，同比增长287.2%；净利润3554万美元，经调整净利润5123万美元，经营活动现金流转正。这是英硅智能上市后发布的首份半年报，公司也由此前的亏损转为盈利。从收入结构看，药物研发与管线开发仍是主要来源。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608313860072952.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608313860072952.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CHAT","QTOC","BIOY","AGIX","GDOC","IPOS","LFSC","WRND","GSKH","APXH","BBP","BK4585","SBIO","IBB","XLVI","ARTY","AIPO","PBE","VTHR","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663044177","title":"聯環藥業上半年扭虧為盈 集採續採與創新藥研發協同推進","url":"https://stock-news.laohu8.com/highlight/detail?id=2663044177","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663044177?lang=zh_tw&edition=fundamental","pubTime":"2026-08-30 21:12","pubTimestamp":1788095520,"startTime":"0","endTime":"0","summary":"业绩实现扭亏为盈经营基本面持续改善今年上半年，联环药业经营业绩实现明显改善。对此，联环药业正持续推进相关工作。值得注意的是，联环药业已经开始围绕创新药商业化进行营销体系布局。除LH-1801外，联环药业产品注册申报也取得阶段性进展。从核心产品稳定销售，到集采品种持续放量，再到创新药研发向上市申报环节推进，联环药业正在逐步形成多层次的业务增长支撑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-30/doc-iniqcfmp8061523.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-30/doc-iniqcfmp8061523.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["WRND","GSKH","PBE","BK4588","LFSC","BBP","SBIO","BIOY","APXH","XLVI","BK4585","GDOC","IBB","BK0239","600513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662091790","title":"南京諾令生物科技股份有限公司向港交所提交上市申請書，獨家保薦人為建銀國際。","url":"https://stock-news.laohu8.com/highlight/detail?id=2662091790","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662091790?lang=zh_tw&edition=fundamental","pubTime":"2026-08-28 22:53","pubTimestamp":1787928801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["TBXU","BIOY","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662942093","title":"據港交所文件，維眸生物科技股份有限公司-B向港交所提交上市申請書。","url":"https://stock-news.laohu8.com/highlight/detail?id=2662942093","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662942093?lang=zh_tw&edition=fundamental","pubTime":"2026-08-28 20:52","pubTimestamp":1787921537,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["TBXU","IPOS","BIOY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662752987","title":"博濟醫藥2026年半年報：創新藥研發需求復甦，在手訂單充足，經營現金流明顯下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2662752987","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662752987?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 14:57","pubTimestamp":1787813849,"startTime":"0","endTime":"0","summary":"然而，需警惕新药研发政策变化、项目执行延期及市场竞争加剧带来的风险，同时关注经营现金流与净利润背离的情况。后续需重点关注公司在手订单转化进度、临床前及临床研究服务的毛利率变化趋势，以及经营现金流的改善情况。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1787797151251328663","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BBP","GDOC","XLVI","BK4585","BK0216","SBIO","159399","IBB","BK4588","GSKH","SPHQ","APXH","WRND","300404","LFSC","PBE","BIOY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106797728","title":"美股開盤｜三大指數升跌不一；Meta升逾3%、小鵬汽車升逾3%；生物科技股活躍","url":"https://stock-news.laohu8.com/highlight/detail?id=1106797728","media":"美股开盘","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106797728?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 21:30","pubTimestamp":1787751055,"startTime":"0","endTime":"0","summary":"投资者在英伟达财报公布前保持观望，市场情绪较为谨慎。公司拟通过部分赔偿及功能调整降低监管不确定性，股价盘前显著反弹。美国第二季度实际GDP年化季率维持1.5%。美国7月核心PCE同比增长3.3%，通胀黏性仍存。管理层警示激烈竞争对利润率造成压力，股价盘后回落近4%。营收及利润双双下滑，显示美国消费者支出放缓。公司宣称AI可服务的潜在市场规模高达30万亿美元，市场热议其估值合理性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TBXU","BK4099","BK1610","BK4505","LU0593848301.USD","XPEG","BK4555","BK4551","BK1575","BK1119","BIOY","XPEV","BK1588","EVS.SI","09868","BK1539","BK4526","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660472972","title":"港股早評：三大指數高開逾1.1%，生物科技股、黃金股大漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2660472972","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660472972?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 09:37","pubTimestamp":1787189821,"startTime":"0","endTime":"0","summary":"美股止住三连跌，日韩股市大幅反弹。港股三大指数集体高开，恒指涨1.11%，国指涨1.27%，恒生科技指数涨1.69%。大型科网股全线上涨，京东涨近3%，美团、阿里巴巴涨2%，腾讯、小米、百度皆上涨；mRNA肿瘤疫苗三期大获成功，全产业链迎来价值重估，生物医药股大涨，康希诺生物、云顶新耀大涨15%，金斯瑞生物科技大涨13%，金价大涨，黄金股领衔有色金属股上涨，另外，消费电子股、海运股、煤炭股部分走低。(格隆汇)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260820/32340660.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK4588","VXUS","159562","GLDW","BIOY","TBXU","KCAI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660476170","title":"AI生物科技股Twist Bioscience升逾22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660476170","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660476170?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 06:26","pubTimestamp":1787178401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["AGIX","CHAT","AIPO","VTHR","QTOC","ARTY","BIOY","TBXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660447273","title":"受利好消息提振，美股生物科技股普漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2660447273","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660447273?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 19:21","pubTimestamp":1787138473,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["TBXU","BIOY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660304824","title":"深圳易慕峯生物科技股份有限公司向港交所提交IPO申請，華泰金融控股（香港）為保薦人兼整體協調人。","url":"https://stock-news.laohu8.com/highlight/detail?id=2660304824","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660304824?lang=zh_tw&edition=fundamental","pubTime":"2026-08-18 07:26","pubTimestamp":1787009193,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["REDS","KCE","FRHC","159940","IPOS","TBXU","BK4127","BIOY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659504119","title":"中國銀河證券：實驗動物為創新藥研發剛需 小鼠+猴雙主線高景氣","url":"https://stock-news.laohu8.com/highlight/detail?id=2659504119","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659504119?lang=zh_tw&edition=fundamental","pubTime":"2026-08-14 15:07","pubTimestamp":1786691225,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国银河证券发布研报称，实验动物为创新药研发刚需，行业壁垒深厚，两大细分赛道具备中长期成长逻辑：人源化小鼠赛道成长确定性更强、周期波动平缓;实验猴赛道供给约束强，短期价格上行带来显著业绩弹性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601881","BK0276","BK1147","06881","BIOY","GDOC","LFSC","WRND","GSKH","BK0188","APXH","BBP","BK4585","SBIO","IBB","XLVI","BK1564","161027","PBE","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658903675","title":"百花醫藥股價嚴重異常波動：主營小分子化學仿製藥CRO業務 不涉及創新藥研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2658903675","media":"央广财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658903675?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 21:27","pubTimestamp":1786541220,"startTime":"0","endTime":"0","summary":"8月12日，百花医药（维权）（600721.SH）发布公告称，公司股票连续10个交易日内日收盘价格涨幅偏离值累计超过100%，根据上交所的有关规定，属于股票交易严重异常波动情形。公司是以小分子化学仿制药研发为主的CRO企业，不涉及创新药研发。公司2026年第一季度实现营业收入6718.29万元，同比下降30.68%，归属于上市公司股东的净利润664.27万元，同比下降67.94%。目前公司主营业务未发生重大变化，市场环境、行业政策没有发生重大调整，股价短期内连续上涨，涨幅与公司经营情况严重偏离。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-12/doc-ininamih5206238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BBP","PBE","GSKH","LFSC","BK0102","GDOC","600721","BK4585","BK4588","BK0216","SBIO","WRND","APXH","IBB","BIOY","XLVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658692990","title":"百花醫藥(600721.SH)：不涉及創新藥研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2658692990","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658692990?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 20:03","pubTimestamp":1786449780,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LFSC","WRND","BBP","APXH","BK4588","BIOY","GDOC","GSKH","SBIO","PBE","IBB","XLVI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658667990","title":"百花醫藥(600721.SH)：不涉及創新藥研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2658667990","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658667990?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 20:03","pubTimestamp":1786449780,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百花医药(600721.SH)发布股票交易风险提示公告称，公司是以小分子化学仿制药研发为主的CRO企业，主营业务是为客户提供小分子化仿药为主的药物研发注册“一站式”全流程服务，主要研发项目多来自于客户委托加部分的公司自主立项，不涉及创新药研发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478640.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["WRND","SBIO","LFSC","PBE","APXH","BK0102","BK0216","GDOC","BIOY","BK4585","BBP","GSKH","XLVI","IBB","BK4588","600721"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658962968","title":"東方證券：AI重構創新藥研發底座 國內相關產業鏈公司亦有望受益","url":"https://stock-news.laohu8.com/highlight/detail?id=2658962968","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658962968?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 14:06","pubTimestamp":1786428403,"startTime":"0","endTime":"0","summary":"东方证券主要观点如下：技术颠覆成本，AI重构制药“快与省”是中国创新药崛起的底层逻辑，根基是人才红利和成本优势。专家与AI协同，将真正提升新药研发的成功率并缩短周期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478422.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["GDOC","BK4588","AIPO","LFSC","BK1147","IBB","BIOY","BK4585","SBIO","BK0012","BK0028","BK1564","BK0188","BK0183","CHAT","PBE","WRND","ARTY","APXH","600958","QTOC","03958","BBP","BK0276","XLVI","VTHR","GSKH","AGIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653584157","title":"創新藥研發加速遇「猴荒」","url":"https://stock-news.laohu8.com/highlight/detail?id=2653584157","media":"三里河","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653584157?lang=zh_tw&edition=fundamental","pubTime":"2026-07-22 16:21","pubTimestamp":1784708497,"startTime":"0","endTime":"0","summary":"“要站在‘猴’里，不要像猴子一样站在那里。”资本市场从来不缺故事。近期，昭衍新药业绩暴增，原因是实验猴市场价格上涨，带动公司手里的“猴子资产”大幅增值，多家相关概念公司股价也跟风大涨。甚至有人顺藤摸瓜，挖出了“香蕉概念”。网友戏称：这是产业链挖掘最深的一次。一只猴子，为什么能扰动资本市场？答案藏在药物的研发链条里。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607223817277458.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607223817277458.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["WRND","BIOY","BK4585","GSKH","BBP","BK4588","IBB","GDOC","SBIO","LFSC","PBE","XLVI","APXH"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":16,"code":"91000000","status":"200"}]}}